1. Genetics and Genomics

Evaluating the effect of metabolic traits on oral and oropharyngeal cancer risk using Mendelian randomization

  1. Mark Gormley  Is a corresponding author
  2. Tom Dudding
  3. Steven J Thomas
  4. Jessica Tyrrell
  5. Andrew R Ness
  6. Miranda Pring
  7. Danny Legge
  8. George Davey Smith
  9. Rebecca C Richmond
  10. Emma E Vincent
  11. Caroline Bull
  1. MRC Integrative Epidemiology Unit, Population Health Sciences, Bristol Medical School, University of Bristol, United Kingdom
  2. Bristol Dental Hospital and School, University of Bristol, United Kingdom
  3. University of Exeter Medical School, RILD Building, RD&E Hospital, United Kingdom
  4. University Hospitals Bristol and Weston NHS Foundation Trust National Institute for Health Research Bristol Biomedical Research Centre, University of Bristol, United Kingdom
  5. Translational Health Sciences, Bristol Medical School, University of Bristol, United Kingdom
https://doi.org/10.7554/eLife.82674
Share this article
Cite this article
  1. Mark Gormley
  2. Tom Dudding
  3. Steven J Thomas
  4. Jessica Tyrrell
  5. Andrew R Ness
  6. Miranda Pring
  7. Danny Legge
  8. George Davey Smith
  9. Rebecca C Richmond
  10. Emma E Vincent
  11. Caroline Bull
(2023)
Evaluating the effect of metabolic traits on oral and oropharyngeal cancer risk using Mendelian randomization
eLife 12:e82674.
https://doi.org/10.7554/eLife.82674
  2. Download BibTeX
  3. Download .RIS

Abstract

A recent World Health Organization report states that at least 40% of all cancer cases may be preventable, with smoking, alcohol consumption, and obesity identified as three of the most important modifiable lifestyle factors. Given the significant decline in smoking rates, particularly within developed countries, other potentially modifiable risk factors for head and neck cancer warrant investigation. Obesity and related metabolic disorders such as type 2 diabetes (T2D) and hypertension have been associated with head and neck cancer risk in multiple observational studies. However, adiposity has also been correlated with smoking, with bias, confounding or reverse causality possibly explaining these findings. To overcome the challenges of observational studies, we conducted two-sample Mendelian randomization (inverse variance weighted [IVW] method) using genetic variants which were robustly associated with adiposity, glycaemic and blood pressure traits in genome-wide association studies (GWAS). Outcome data were taken from the largest available GWAS of 6034 oral and oropharyngeal cases, with 6585 controls. We found limited evidence of a causal effect of genetically proxied body mass index (BMI; OR IVW = 0.89, 95% CI 0.72–1.09, p = 0.26 per 1 standard deviation in BMI [4.81kg/m2]) on oral and oropharyngeal cancer risk. Similarly, there was limited evidence for related traits including T2D and hypertension. Small effects cannot be excluded given the lack of power to detect them in currently available GWAS.

Editor's evaluation

This work presents valuable findings on the causal association of metabolic traits and head and neck cancers. The evidence supporting the conclusion is convincing, with rigorous and comprehensive data analysis. The work will be of interest to cancer epidemiologists, especially those working on head and neck cancer.

https://doi.org/10.7554/eLife.82674.sa0

Introduction

Head and neck squamous cell carcinoma (HNC), which includes oral and oropharyngeal cancer is the seventh most common cancer, accounting for more than 660,000 new cases and 325,000 deaths annually worldwide (Johnson et al., 2020; Sung et al., 2021). Established risks include tobacco use, alcohol consumption (Hashibe et al., 2009), and human papillomavirus (HPV) infection, mainly associated with oropharyngeal cancer and thought to be sexually transmitted (Gillison et al., 2015). A recent World Health Organization (WHO) report states that at least 40% of all cancer cases may be preventable, with smoking, alcohol consumption, and obesity identified as three of the most important modifiable lifestyle factors (World Health Organization, 2022). Smoking behaviour is declining, particularly in developed countries (Dai et al., 2022) and it has been projected that obesity could even supersede smoking as the primary driver of cancer in the coming decades (World Health Organization, 2022). Despite changes in smoking rates, the incidence of HNC continues to rise and a changing aetiology has been proposed (Conway et al., 2018; Thomas et al., 2018). Therefore, less established risks such as obesity and its related metabolic traits warrant investigation in HNC. However, obesity has been correlated with other HNC risk factors such as smoking (Carreras-Torres et al., 2018), alcohol (Carter et al., 2019a) and educational attainment (Carter et al., 2019b), meaning independent effects are difficult to establish.

Obesity is now considered to increase the risk of at least 13 different types of cancer including breast, colorectal, gastric, and oesophageal (Centers for Disease Control and Prevention, 2021), but the effect on HNC risk remains unclear [World Health Organization, 2022]. Public health strategies have been unsuccessful in addressing the current obesity epidemic at the population level, which could result in more cancer cases in the years to come (Davey, 2004). Obesity and related metabolic traits such as type 2 diabetes (T2D), hypertension, and dyslipidaemia have all been associated with HNC in multiple observational studies. In the largest pooled analysis, obesity defined by higher body mass index (BMI) was associated with a protective effect for HNC in current smokers (hazard ratio [HR] 0.76, 95% confidence intervals [95% CI] 0.71–0.82, p <0.0001, per 5  kg/m2) and conversely, a higher risk in never smokers (HR 1.15, 95% CI 1.06–1.24 per 5  kg/m2, p < 0.001) (Gaudet et al., 2015). In the same study, a greater waist circumference (WC) (HR  1.04, 95% CI 1.03–1.05 per 5 cm, p < 0.001) and waist-to-hip ratio (WHR) (HR 1.07, 95% CI 1.05–1.09 per 0.1 unit, p < 0.001) were associated with increased HNC risk, which did not vary by smoking status (Gaudet et al., 2015). However, more recent cohort studies have failed to show a clear association between BMI and HNC (Cao et al., 2020; Recalde et al., 2021; Gribsholt et al., 2020; Jiang et al., 2021; Ward et al., 2017). A random-effects meta-analysis of observational studies showed an increased association between T2D and oral and oropharyngeal cancer (risk ratio [RR] of 1.15, 95% CI 1.02–1.29, p < 0.001 [Gong et al., 2015]). This result is consistent with more recent independent cohorts (Jiang et al., 2021; Kim et al., 2021; Kim et al., 2019; Saarela et al., 2019). Hypertension (defined as a systolic blood pressure [SBP] >130 mmHg or diastolic blood pressure [DBP] >85 mmHg) has been correlated with HNC risk across multiple studies (Christakoudi et al., 2020; Kim et al., 2021; Kim et al., 2019; Seo et al., 2020; Stocks et al., 2012). Nonetheless, selection bias, confounding, or reverse causation may explain the findings from these studies.

Mendelian randomization (MR) is an analytical approach which attempts to overcome the challenges of conventional epidemiological studies. The method uses germline genetic single nucleotide polymorphisms (SNPs), which are randomly assorted during meiosis (and fixed at conception), to estimate the causal effects of exposures on disease outcomes (Smith and Ebrahim, 2003; Davey Smith and Hemani, 2014; Sanderson et al., 2022). MR makes three key assumptions, as described in Figure 1 (Smith and Ebrahim, 2003; Davey Smith and Hemani, 2014). To instrument metabolic traits, we selected genetic variants associated (p < 5 × 10−8) with traits of interest identified by previously conducted genome-wide association studies (GWAS; Supplementary file 1). Further detail on MR methods and sensitivity analyses is given in the Materials and methods.

Figure 1
Download asset Open asset
Directed acyclic graph (DAG) depicting Mendelian randomization applied to this study.

Genetic variants (G) can act as proxies or instruments to investigate if an exposure (X) is associated with a disease outcome (Y). Causal inference can be made between X and Y if the following conditions are upheld. (1) The genetic variants which make up the instrument are valid and reliably associated with the exposure (i.e., the ‘relevance assumption’); (2) There is no measured or unmeasured confounding of the association between the genetic instrument and the outcome (i.e., the ‘exchangeability’ assumption); (3) There is no independent pathway between the genetic instrument and the outcome, except through the exposure (i.e., the ‘exclusion restriction principle’).

Using MR, we recently found limited evidence for a role of circulating lipid traits in oral and oropharyngeal cancer risk (Gormley et al., 2021), however other metabolic traits remain untested in an MR framework. This study aims to examine the causal effect of metabolic traits on the risk of oral and oropharyngeal cancer using two-sample MR. Specifically, we will examine adiposity measures (BMI, WC, WHR), glycaemic traits (T2D, glycated haemoglobin [HbA1c], fasting glucose [FG], fasting insulin [FI]), and blood pressure (SBP, DBP). Given the potential correlation of metabolic traits and established HNC risk factors, further evaluation of instrument-risk factor effects including smoking, alcohol, risk tolerance (as a proxy for sexual behaviour), and educational attainment was carried out using MR.

Results

F-statistics of genetic instruments for metabolic traits ranged from 33.3 to 133.6, indicating sufficient instrument strength for MR analyses (Supplementary file 2, Table 2A). Genetic instruments were estimated to explain between 0.5% (FI) and 4% (BMI) of their respective metabolic trait (Supplementary file 2, Table 2A). Based on the results of prior observational studies we would expect to detect OR of >1.2 for a clinically meaningful effect of metabolic traits on oral and oropharyngeal cancer. Figure 2—figure supplement 1 displays power estimates for MR analyses. In analyses where BMI was the exposure, we had 80% power to detect an association with an OR of 1.2 or more at an α of 0.05 for combined oral and oropharyngeal cancer. Power was lower for other metabolic traits and reduced when stratifying analyses by subsite.

Estimated effect of adiposity on oral and oropharyngeal cancer risk

There was limited evidence of an effect of higher BMI or WHR on combined oral and oropharyngeal cancer (OR IVW = 0.89, 95% CI 0.72–1.09, p = 0.26, per 1 standard deviation [SD] in BMI [4.81 kg/m2] and OR IVW = 0.98, 95% CI 0.74–1.29, p = 0.88, per 1 SD in WHR [0.10 unit]) (Table 1, Figure 2, Figure 2—figure supplements 2 and 3). Results were consistent when analyses were stratified by subsite (Table 1). WC, another measure of adiposity did show a protective direction of effect (OR IVW = 0.73, 95% CI 0.52–1.02, p = 0.07, per 1 SD increase in WC [0.09 unit]), particularly in the oropharyngeal subsite (OR IVW = 0.66, 95% CI 0.43–1.01, p = 0.06, per 1 SD increase in WC [0.09 unit]) (Table 1, Figure 2, Figure 2—figure supplement 4).

Figure 2 with 19 supplements see all
Download asset Open asset
Mendelian randomization results of genetically proxied metabolic disorders with risk of oral and oropharyngeal cancer including sensitivity analyses in GAME-ON.

Oral and oropharyngeal cancer combined n = 6034, oral cancer n = 2990 and oropharyngeal cancer n = 2641. Abbreviations: IVW, inverse variance weighted; OR, odds ratio with 95% confidence intervals; BMI, body mass index; WC, waist circumference; WHR, waist–hip ratio; T2D, type 2 diabetes mellitus; FG, fasting glucose; FI, fasting insulin; HbA1c, glycated haemoglobin; SBP, systolic blood pressure; DBP, diastolic blood pressure. OR are expressed per 1 standard deviation (SD) increase in genetically predicted BMI (4.81 kg/m2), WC (0.09 unit), WHR (0.10 unit), T2D (1-log unit higher odds of T2D), FG (1-log unit increase in mmol/l fasting glucose), FI (1-log unit increase in mmol/L fasting insulin), HbA1c (1-log unit % higher glycated haemoglobin), SBP (1 unit mmHg increase), and DBP (1 unit mmHg increase).

Table 1
Mendelian randomization results of genetically proxied metabolic traits with risk of oral and oropharyngeal cancer in GAME-ON.
IVWWeighted medianWeighted modeMR-Egger
 ExposureOutcomeExposure/outcome sourceOutcome
N		Number of
SNPs		OR (95% CI)pOR (95% CI)pOR (95% CI)pOR (95% CI)p
 BMIOral and oropharyngeal cancer combinedPulit et al.
GWAS/GAME-ON		60342720.89 (0.72, 1.09)0.260.71 (0.50, 1.00)0.050.63 (0.37, 1.04)0.070.66 (0.40, 1.10)0.11
Oral cancer29902720.92 (0.71, 1.19)0.530.83 (0.55, 1.28)0.400.79 (0.38, 1.62)0.520.75 (0.39, 1.41)0.37
Oropharyngeal cancer26412720.89 (0.68, 1.15)0.360.75 (0.50, 1.13)0.170.53 (0.27, 1.03)0.060.56 (0.29, 1.07)0.08
 WCOral and oropharyngeal cancer combinedShungin et al.
GWAS/GAME-ON		6034430.73 (0.52, 1.02)0.070.64 (0.40, 1.05)0.080.67 (0.36, 1.26)0.220.43 (0.17, 1.08)0.08
Oral cancer2990430.82 (0.53, 1.26)0.360.66 (0.36, 1.21)0.180.67 (0.32, 1.39)0.290.54 (0.17, 1.76)0.31
Oropharyngeal cancer2641430.66 (0.43, 1.01)0.060.56 (0.30, 1.05)0.070.37 (0.17, 0.83)0.020.30 (0.09, 0.98)0.05
 WHROral and oropharyngeal cancer combinedPulit et al. GWAS/GAME-ON60341760.98 (0.74, 1.29)0.880.98 (0.64, 1.49)0.920.95 (0.45, 2.00)0.891.80 (0.87, 3.71)0.11
Oral cancer29901761.18 (0.84, 1.65)0.351.00 (0.58, 1.73)0.990.69 (0.29, 1.67)0.412.49 (1.02, 6.12)0.05
Oropharyngeal cancer26411760.83 (0.59, 1.14)0.250.88 (0.51, 1.50)0.630.93 (0.37, 2.30)0.871.19 (0.50, 2.86)0.70
 T2DOral and oropharyngeal cancer combinedVujkovic et al. GWAS/GAME-ON60342540.92 (0.84, 1.01)0.090.85 (0.74, 0.97)0.020.84 (0.71, 1.01)0.060.91 (0.77, 1.09)0.31
Oral cancer29902540.94 (0.84, 1.05)0.270.84 (0.72, 0.99)0.040.82 (0.66, 1.02)0.080.88 (0.71, 1.08)0.22
 Oropharyngeal cancer26412540.94 (0.84, 1.05)0.270.89 (0.73, 1.10)0.291.02 (0.80, 1.30)0.881.00 (0.81, 1.24)0.99
 HbA1c Oral and oropharyngeal cancer combinedWheeler et al.
GWAS/GAME-ON (Lesseur et al., 2016)		6034370.56 (0.32, 1.00)0.050.52 (0.23, 1.20)0.120.54 (0.24, 1.21)0.140.37 (0.13, 1.05)0.07
Oral cancer2990370.48 (0.24, 0.93)0.030.51 (0.18, 1.41)0.190.44 (0.15, 1.29)0.140.30 (0.09, 1.03)0.06
 Oropharyngeal cancer2641370.66 (0.31, 1.40)0.280.49 (0.15, 1.57)0.230.57 (0.18, 1.85)0.350.43 (0.11, 1.68)0.23
 FGOral and oropharyngeal cancer combinedLagou et al.
GWAS/
GAME-ON (Lesseur et al., 2016)		6034281.06 (0.68, 1.66)0.791.20 (0.62, 2.30)0.591.13 (0.60, 2.12)0.711.11 (0.48, 2.56)0.80
Oral cancer2990281.05 (0.58, 1.92)0.871.15 (0.48, 2.72)0.750.99 (0.44, 2.23)0.991.25 (0.39, 4.01)0.70
Oropharyngeal cancer2641281.39 (0.77, 2.51)0.281.24 (0.51, 3.03)0.631.36 (0.59, 3.18)0.481.38 (0.45, 4.18)0.58
 FIOral and oropharyngeal cancer combinedLagou et al.
GWAS/GAME-ON		6034170.81 (0.23, 2.89)0.750.75 (0.20, 2.87)0.680.60 (0.03, 10.79)0.740.11 (0.001, 22.47)0.43
Oral cancer2990170.96 (0.22, 4.16)0.960.46 (0.08, 2.47)0.370.45 (0.01, 19.02)0.680.21 (0.0004, 107.21)0.63
Oropharyngeal cancer2641170.68 (0.16, 2.87)0.590.66 (0.12, 3.67)0.630.48 (0.05, 4.99)0.550.09 (0.0002, 40.04)0.45
 SBPOral and oropharyngeal cancer combinedEvangelou et al., 2018 GWAS/GAME-ON (Lesseur et al., 2016)6034831.00 (0.97, 1.03)0.890.99 (0.94, 1.03)0.550.98 (0.88, 1.09)0.661.06 (0.92, 1.23)0.39
Oral cancer2990831.01 (0.96, 1.06)0.740.99 (0.93, 1.04)0.650.95 (0.84, 1.08)0.481.09 (0.90, 1.33)0.37
Oropharyngeal cancer2641830.99 (0.95, 1.03)0.650.99 (0.94, 1.05)0.771.00 (0.88, 1.13)0.941.03 (0.87, 1.23)0.71
 DBPOral and oropharyngeal cancer combinedEvangelou et al., 2018 GWAS/GAME-ON6034640.93 (0.87, 1.00)0.050.94 (0.86, 1.04)0.221.10 (0.88, 1.38)0.420.99 (0.80, 1.24)0.95
Oral cancer2990640.95 (0.87, 1.04)0.260.96 (0.86, 1.07)0.451.17 (0.88, 1.56)0.280.97 (0.74, 1.27)0.81
Oropharyngeal cancer2641640.92 (0.84, 1.00)0.050.94 (0.84, 1.05)0.291.10 (0.86, 1.41)0.451.00 (0.75, 1.30)0.93

  1. OR are expressed per 1 standard deviation (SD) increase in genetically predicted BMI (4.81 kg/m2), WC (0.09 unit), WHR (0.10 unit), T2D (1-log unit higher odds of T2D), FG (1-log unit increase in mmol/L fasting glucose), FI (1-log unit increase in mmol/L fasting insulin), HbA1c (1-log unit % higher glycated haemoglobin), SBP (1 unit mmHg increase), and DBP (1 unit mmHg increase).

  2. IVW, inverse variance weighted; OR, odds ratio; CI, confidence intervals; p, p-value; BMI, body mass index; WC, waist circumference; WHR, waist–hip ratio; T2D, type 2 diabetes mellitus; FG, fasting glucose; FI, fasting insulin; HbA1c, glycated haemoglobin; SBP, systolic blood pressure; DBP, diastolic blood pressure.

Estimated effect of glycaemic traits on oral and oropharyngeal cancer risk

There was limited evidence for an effect of genetically proxied T2D on combined oral and oropharyngeal cancer [OR IVW = 0.92, 95% CI 0.84–1.01, p = 0.09, per 1-log unit higher odds of T2D (Table 1, Figure 2, Figure 2—figure supplement 5)]. Traits related to diabetes, including HbA1c resulted in a weak protective effect on combined oral and oropharyngeal cancer risk (OR IVW = 0.56, 95% CI 0.32–1.00, p = 0.05, per 1-log unit % higher HbA1c), which remained only in the oral subsite (OR IVW = 0.48, 95% CI 0.24–0.93, p = 0.03, per 1-log unit % higher HbA1c) following stratification (Table 1, Figure 2, Figure 2—figure supplement 6). Conversely, there was limited evidence of an effect for FG (OR IVW = 1.06, 95% CI 0.68–1.66, p = 0.79, per 1-log unit increase in mmol/l fasting glucose) (Table 1, Figure 2, Figure 2—figure supplement 7) or FI (OR IVW = 0.81, 95% CI 0.23–2.89, p = 0.75, per 1-log unit increase in mmol/l FI) on combined oral and oropharyngeal cancer risk (Table 1, Figure 2, Figure 2—figure supplement 8).

Estimated effect of increased blood pressure oral and oropharyngeal cancer risk

Finally, there was limited evidence for an effect of SBP on risk of combined oral and oropharyngeal cancer (OR IVW = 1.00, 95% CI 0.97–1.03, p = 0.89, per 1 unit mmHg increase in systolic blood pressure) (Table 1, Figure 2, Figure 2—figure supplement 9), which did not change when stratified by subsite. However, there was some weak evidence for a protective effect of DBP on risk of combined oral and oropharyngeal cancer (OR IVW = 0.93, 95% CI 0.87–1.00, p = 0.05, per 1 unit mmHg increase in DBP) (Table 1, Figure 2, Figure 2—figure supplement 10).

Sensitivity analyses

We conducted MR-Egger, weighted median, and weighted mode analyses in addition to IVW (Table 1, Figure 2). The results of these analyses generally followed the same pattern as the IVW results reported above, however, there were a number of exceptions. The results for HbA1c were not robust to sensitivity testing (p > 0.05 across methods) (Table 1, Figure 2). In the analysis of T2D on combined oral and oropharyngeal cancer, the weighted median result provided evidence for a weak protective effect (OR weighted median 0.85, 95% CI 0.74–0.97, p = 0.02). This effect appeared mainly in the oral subsite (OR weighted median 0.84, 95% CI 0.72–0.99, p = 0.04). Furthermore, in the analysis of WC on oropharyngeal cancer risk, the weighted mode supported IVW result, providing evidence of a protective effect (OR weighted mode 0.37, 95% CI 0.17–0.83, p = 0.02) (Table 1, Figure 2).

There was clear evidence of heterogeneity in the SNP effect estimates OR IVW and MR-Egger regression for WHR (Q IVW = 213.04, p = 0.03; Q MR-Egger = 209.24, p = 0.04), T2D (Q IVW = 328.24, p < 0.01; Q MR-Egger = 328.21, p < 0.01), FI (Q IVW = 32.87, p < 0.01; Q MR-Egger = 31.63, p < 0.01), and DBP (Q IVW = 95.82, p < 0.01; Q MR-Egger = 95.22, p < 0.01) (Supplementary file 2, Table 2B). MR-Egger intercepts were not strongly indicative of directional pleiotropy (Supplementary file 2, Table 2C), but there were outliers present on visual inspection of scatter plots (Figure 2—figure supplements 11–19). MR-PRESSO identified 19 outliers for BMI, 2 outliers for WC, 12 outliers for WHR, 23 outliers for T2D, 4 outliers for HbA1c, 1 outlier for FG, 3 outliers for FI, 5 outliers for SBP, and 7 outliers for DBP (Supplementary file 2, Table 2D–E). When correcting for these outliers, this yielded effects consistent with the primary IVW analysis except for adiposity and T2D instruments, which demonstrated a protective effect on combined oral and oropharyngeal cancer risk when outliers were excluded: BMI (OR IVW = 0.77, 95% CI 0.62–0.94, p = 0.01, per 1 SD in BMI [4.81 kg/m2]); WC (OR IVW = 0.65, 95% CI 0.47–0.89, p = 0.01, per 1 SD in WC [0.09 unit]), and T2D (OR IVW = 0.91, 0.84–0.99, p = 0.03, per 1-log unit higher odds of T2D) (Supplementary file 2, Table 2F). Where there was evidence of violation of the negligible measurement error (NOME) assumption for WC, FI, SBP, and DBP (i.e., I2 statistic <0.90) (Supplementary file 2, Table 2G), MR-Egger was performed with SIMEX correction. SIMEX effects were consistent with the null, except for SBP where an increased risk effect on combined oral and oropharyngeal cancer was found (OR IVW = 1.15, 95% CI 1.05–1.26, p < 0.01, per 1 unit mmHg increase in diastolic blood pressure) (Supplementary file 2, Table 2H).

Evaluating instrument-risk factor effects

Where there was evidence for an effect of BMI, WC, WHR, T2D, HbA1c, and DBP on oral and oropharyngeal cancer, we carried out further MR analysis to determine causal effects of these metabolic instruments on established risk HNC risk factors. Adiposity measures showed a strong causal effect on the risk of smoking initiation: BMI [Beta IVW 0.21 (standard error (SE) 0.03), p < 0.001, per 1 SD increase in BMI (4.81 kg/m2)], WC [Beta IVW 0.21 (SE 0.05), p < 0.001, per 1 SD increase in WC (0.09 unit)], and WHR [Beta IVW 0.18 (SE 0.03), p < 0.001, per 1 SD increase in WHR (0.10 unit)] (Supplementary file 2, Table 2I). Smaller, yet similar effects were found between adiposity measures and the comprehensive smoking index: BMI [Beta IVW 0.10 (SE 0.01), p < 0.001, per 1 SD increase in BMI (4.81 kg/m2)], WC [Beta IVW 0.10 (SE 0.02), p < 0.001, per 1 SD increase in WC (0.09 unit)], and WHR [Beta IVW 0.09 (SE 0.01), p < 0.001, per 1 SD increase in WHR (0.10 unit)].

There was weaker evidence for an effect of BMI, WC, and genetic liability to T2D on consumption of alcoholic drinks per week: BMI [Beta IVW −0.04 (SE 0.01), p < 0.01, per 1 SD increase in BMI (4.81 kg/m2)], WC [Beta IVW −0.09 (SE 0.02), p < 0.001, per 1 SD increase in WC (0.09 unit)] and T2D [Beta IVW −0.02 (SE 0.01), p < 0.001, per 1-log unit higher odds of T2D]. BMI [Beta IVW 0.04 (SE 0.01), p < 0.001, per 1 SD increase in BMI (4.81 kg/m2)] and WHR [Beta IVW 0.04 (SE 0.02), p = 0.02, per 1 SD increase in WHR (0.10 unit)] were also estimated to increase general risk tolerance. Similarly, increased BMI or WHR and genetic liability to T2D were estimated to decrease educational attainment (years of schooling): BMI [Beta IVW −0.16 (SE 0.02), p < 0.001, per 1 SD increase in BMI (4.81 kg/m2)], WHR [Beta IVW −0.11 (SE 0.02), p < 0.001, per 1 SD increase in WHR (0.10 unit)], and T2D [Beta IVW −0.02 (SE 0.01), p < 0.01, per 1-log unit higher odds of T2D]. However, there was strong evidence of both heterogeneity (Supplementary file 2, Table 2J) and genetic pleiotropy (Supplementary file 2, Table 2K) across most instrument-risk factor effects. With the exception of alcohol drinks per week, the estimated instrument-risk factor effects remained unchanged following the removal of outlier SNPs detected by MR-PRESSO (Supplementary file 2, Table 2L).

Discussion

In this MR study, we found limited evidence to support a causal role of genetically predicted metabolic traits in oral and oropharyngeal cancer, suggesting the risk may have been previously overestimated in observational studies. However, small effects cannot be excluded given the lack of power to detect them in currently available HNC GWAS. Where weak evidence for an effect was found (i.e., a protective effect of HbA1c), these results were not robust to sensitivity analysis, including outlier correction. There was also evidence for instrument-risk factor effects, suggesting smoking may be a mediator between adiposity and HNC.

There are several biological mechanisms linking metabolic traits and cancer, but these have not been well explored in HNC (Gatenby and Gillies, 2004; Grimberg, 2003; Tseng et al., 2014). Dysregulated metabolism is likely linked to the probability a cancer develops and progresses, given that tumours must adapt to satisfy the bioenergetic and biosynthetic demands of chronic cell proliferation via metabolic reprogramming, enhancing or suppressing the activity of metabolic pathways relative to that in benign tissue (DeNicola and Cantley, 2015). In the largest pooled analysis of 17 case–control studies, increasing BMI was associated with a higher risk of overall HNC, but when stratified by subsite the effect was mainly in the larynx (HR 1.42, 95% CI 1.19–1.70 per 5  kg/m2, p < 0.001) (Gaudet et al., 2015). Laryngeal cancer was not included in our study given that GWAS summary data were not available for this subsite and future analysis of this region is therefore warranted given this is the most smoking determined cancer. BMI effects on both the oral (HR 1.10, 95% CI 0.97–1.25, p = 0.14) and oropharyngeal cancer (HR 0.98, 95% CI 0.84–1.14, p = 0.77) subsites were consistent with the effects found in our study (oral cancer OR 0.92, 95% CI 0.71–1.19, p = 0.53; oropharyngeal cancer OR 0.89, 0.68–1.15, p = 0.36) (Gaudet et al., 2015). Conversely, the same pooled analysis found an increased risk for both WC (HR 1.09, 95% CI 1.03–1.16, p = 0.006) and WHR (HR 1.17, 95% CI 1.02–1.34, p = 0.02), mainly in the oral subsite which were not replicated in our MR analysis. Varying patterns of results for these anthropometric measures have been found when stratifying by smoking status within observational studies (Gaudet et al., 2015). The relationship between obesity and HNC is complex. There appears to be a positive association between low BMI (<18.5  kg/m2) and HNC risk, and a protective effect of BMI on HNC risk in current smokers but conversely, a higher risk in never smokers (Gaudet et al., 2015). This suggests smoking is a confounder, both as an established risk factor for HNC and in its correlation with weight, with nicotine affecting metabolic energy expenditure, leading to reduced calorie absorption and appetite suppression (Williamson et al., 1991). Instrument-risk factor effect estimates from this study suggest smoking is also a mediator, through which metabolic traits such as BMI influence HNC risk. Smoking could be acting as both a mediator and a confounder, since the relationship between BMI and smoking is bi-directional (i.e., smoking reduces BMI and higher BMI in turn increases the likelihood of smoking), which has been demonstrated in previous MR studies (Carreras-Torres et al., 2018; Taylor et al., 2019).

Despite metabolic syndrome (including hypertension, central obesity, elevated triglyceride, low High-density lipoprotein cholesterol (HDL-C), and insulin resistance) being strongly associated with common cancers such as colorectal and breast (Esposito et al., 2012), this does not appear to be the case in HNC. A recent prospective study of 474,929 participants from UK Biobank investigating the effect of metabolic syndrome suggested those with the condition had no increased HNC risk (HR 1.05, 95% CI 0.90–1.22, p = 0.560) (Jiang et al., 2021). No definitive causal effects were detected for individual components of metabolic syndrome components either, supporting our MR results. While another large meta-analysis found individuals with T2D have an elevated risk of oral cancer (Gong et al., 2015), other more recent studies have found this effect to be mostly in laryngeal subsite (HR 1.25, 95% CI 1.12–1.40) which again we could not investigate in this study (Kim et al., 2021). Hypertension is the most consistently reported metabolic trait to have an observational association with HNC risk across the subsites (Christakoudi et al., 2020; Kim et al., 2021; Kim et al., 2019; Seo et al., 2020; Stocks et al., 2012). We did not identify a clear effect of either SBP or DBP on oral or oropharyngeal cancer using MR, again suggesting the possibility of residual confounding in observational studies.

MR was employed in this study in an attempt to overcome the drawbacks of conventional epidemiological studies. However, there are a number of limitations with using this approach and if MR assumptions are violated, this too can generate spurious conclusions. While there was no evidence of weak instrument bias (F statistics >10), there was heterogeneity present in at least four of the instruments (WHR, T2D, FI, and DBP). This is expected to some extent, given that we are instrumenting multiple biological pathways that contribute to complex metabolic phenotypes. The use of multiple related instruments for each metabolic trait may, however, provide some additional confidence in the overall findings. Given the low percentage of variation explained (R2) for some instruments, as well as the relatively small number of oral and oropharyngeal cancer cases, power to detect an effect may have been an issue in some of our analyses.

As with observational studies, there may be issues of measurement error or misclassification in genetic epidemiology, given BMI is simply a function of mass and height and does not specifically measure adiposity. However, BMI has been shown to be an acceptable proxy when used in large samples sizes, correlating with both total body fat (Browning et al., 2011) and total abdominal adipose tissue (Ross et al., 1992), which is thought to present a greater health risk than fat deposited elsewhere. Furthermore, we used a range of adiposity measures including WC and WHR, which may be better proxies of abdominal adiposity, compared to BMI (Lee et al., 2008).

Risk tolerance is challenging to instrument genetically due to measurement error (e.g., as a result of reporting bias) and because it is socially patterned, time-varying as well as context and culture-dependent (Gormley et al., 2022). It may also be a poor proxy for sexual behaviour, despite genetic correlation with these phenotypes given that pleiotropy with other traits such as smoking may be present (Mills et al., 2021). However, genetic instruments are not available specifically for oral sex, which is the conceptually relevant exposure and likely mode of HPV transmission.

SNPs used to proxy these metabolic traits, particularly adiposity measures BMI, WC, and WHR were also strongly associated with smoking. Repeating this analysis in an updated, better powered GWAS is required in order to exclude any potential small effects of metabolic traits on HNC risk via smoking. Given the heterogeneity of these complex metabolic traits, future work could further examine their pathway-specific effects (Udler et al., 2018).

Overall, there was limited evidence for an effect of genetically proxied metabolic traits on oral and oropharyngeal cancer risk. These findings suggest metabolic traits may not be effective modifiable risk factors to prioritize as part of future prevention strategies in HNC, however, small effects cannot be excluded and further replication in larger GWAS is needed. The effect of metabolic traits on the risk of this disease may have been overestimated in previous observational studies, but these cannot be directly compared given the differences in methodological approaches and the interpretation of estimates. Smoking appears to act as a mediator in the relationship between obesity and HNC. Although there is no clear evidence that changing body mass will reduce or increase the risk of HNC directly, dental and medical teams should be aware of the risk of smoking in those who are overweight and therefore the greater risk of cancer when providing smoking cessation and appropriate weight loss advice.

Materials and methods

Two-sample MR was performed using published summary-level data from the largest available GWAS for each metabolic trait.

Exposure summary statistics for metabolic traits

Request a detailed protocol

To instrument metabolic traits, we selected genetic variants associated (p < 5 × 10−8) with traits of interest identified by previously conducted GWAS (Supplementary file 1). Clumping was performed in the TwoSampleMR package to ensure SNPs in each instrument were independent (r2 < 0.001). This accounted for any potential linkage disequilibrium between SNPs, which can lead to overestimation of instrument strength and overly precise effect estimates. Following clumping, genetic instruments were comprised of: 312 SNPs for BMI, from a GWAS meta-analysis of 806,834 individuals of European ancestry, including the Genetic Investigation of ANthropometric Traits (GIANT) consortium and UK Biobank (Pulit et al., 2019) and 209 SNPs for WHR extracted from the same GWAS in 697,734 individuals (Pulit et al., 2019). Forty-five SNPs for WC were taken from a GWAS meta-analysis describing 224,459 individuals of mainly European ancestry (Shungin et al., 2015), 275 SNPs for T2D from the DIAMANTE (DIAbetes Meta-ANalysis of Trans-Ethnic association studies) consortium of 228,499 cases and 1,178,783 controls (Vujkovic et al., 2020), 33 SNPs for FG and 18 SNPs for FI, obtained from a GWAS published by the MAGIC (Meta-Analyses of Glucose and Insulin-Related Traits) Consortium (N = 151,188 and 105,056 individuals of European descent, respectively) (Lagou et al., 2021); 58 SNPs for HbA1c, taken from a meta-analysis of 88,355 individuals from European cohorts (Wheeler et al., 2017); finally, 105 and 78 SNPs for SBP and DBP, respectively, were extracted from a GWAS meta-analysis of over 1million participants in UK Biobank and the International Consortium of Blood Pressure Genome Wide Association Studies (ICBP) (Evangelou et al., 2018; Supplementary file 1).

Outcome summary statistics for oral and oropharyngeal cancer

Request a detailed protocol

We estimated the effects of metabolic traits on risk of oral and oropharyngeal cancer by extracting exposure SNPs (Supplementary file 1) from the largest available GWAS performed on 6034 cases and 6585 controls from 12 studies which were part of the Genetic Associations and Mechanisms in Oncology (GAME-ON) Network (Lesseur et al., 2016). Full details of the included studies, as well as the genotyping and imputation performed, have been described previously (Dudding et al., 2018; Lesseur et al., 2016). In brief, the study population included participants from Europe (45.3%), North America (43.9%), and South America (10.8%). Cancer cases comprised the following the International Classification of Diseases (ICD-10) codes: oral (C02.0–C02.9, C03.0–C03.9, C04.0–C04.9, C05.0–C06.9), oropharyngeal (C01.9, C02.4, C09.0–C10.9), hypopharyngeal (C13.0–C13.9), overlapping (C14 and combination of other sites), and 25 cases with unknown code (other). A total of 954 individuals with cancers of hypopharynx, unknown code or overlapping cancers were excluded. Genomic DNA isolated from blood or buccal cells was genotyped at the Center for Inherited Disease Research (CIDR) using an Illumina OncoArray, custom designed for cancer studies by the OncoArray Consortium (Consortium, 2013). Principle components analysis was performed using approximately 10,000 common markers in low linkage disequilibrium (LD) (r2 < 0.004), minor allele frequency >0.05 and 139 population outliers were removed.

Given the differential association of potential risk factors at each subsite (i.e., smoking, alcohol and HPV infection) (Thomas et al., 2018), we performed stratified MR analyses for oral and oropharyngeal cancer to evaluate potential heterogeneity in effects. For this, we used GWAS summary data on a subset of 2990 oral and 2641 oropharyngeal cases and the 6585 common controls in the GAME-ON GWAS (Lesseur et al., 2016).

Statistical analysis

Request a detailed protocol

Two-sample MR was conducted using the ‘TwoSampleMR’ package in R (version 3.5.3), by integrating SNP associations for each metabolic trait (exposure, sample 1) with those for oral and oropharyngeal cancer in GAME-ON (outcome, sample 2). For exposures, we only used genetic variants reaching GWAS significance (p < 5 × 10−8). The nearest gene was identified using SNPsnap and a distance of ±500 kb (Pers et al., 2015). Firstly, metabolic trait-associated SNPs were extracted from oral and oropharyngeal cancer summary statistics. Exposure and outcome summary statistics were harmonized using the ‘harmonise_data’ function of the TwoSampleMR package so that variant effect estimates corresponded to the same allele. Palindromic SNPs were identified and corrected using allele frequencies where possible (alleles were aligned when minor allele frequencies were <0.3, or were otherwise excluded). For each SNP in each exposure, individual MR effect estimates were calculated using the Wald method (SNP-outcome beta/SNP-exposure beta) (Wald, 1940). Multiple SNPs were then combined into multi-allelic instruments using random-effects IVW meta-analysis.

IVW estimates may be vulnerable to bias if genetic instruments are invalid and are only unbiased in the absence of horizontal pleiotropy or when horizontal pleiotropy is balanced (Hemani et al., 2018). We therefore performed additional sensitivity analyses to evaluate the potential for unbalanced horizontal pleiotropy using weighted median (Bowden et al., 2016a), weighted mode (Hartwig et al., 2017), and MR-Egger (Bowden et al., 2015) methods which are described in detail elsewhere (Lawlor et al., 2019). In short, the weighted median stipulates that at least 50% of the weight in the analysis stems from valid instruments. Weighted mode returns an unbiased estimate of the causal effect if the cluster with the largest weighted number of SNPs for the weighted model are all valid instruments. Instruments are weighted by the inverse variance of the SNP-outcome association (Hartwig et al., 2017).

Finally, MR-Egger provides reliable effect estimates even if variants are invalid and the Instrument Strength Independent of Direct Effect (InSIDE) assumption is violated (Bowden et al., 2015). The InSIDE assumption states that the association between genetic instrument and exposure should not be correlated with an independent path from instrument to the outcome. In the presence of unbalanced pleiotropy when the InSIDE assumption is violated, then the MR-Egger result may be biased (Lawlor et al., 2019). Gene variants must be valid instruments and where there was evidence of violation of the NOME assumption (Bowden et al., 2016b), this was assessed using the I2 statistic and MR-Egger was performed with simulation extrapolation (SIMEX) correction for bias adjustment (Bowden et al., 2016b). The variance of each trait explained by the genetic instrument (R2) was estimated and used to perform power calculations (Brion et al., 2013). F-statistics were also generated. An F-statistic lower than 10 was interpreted as indicative of a weak instrument bias (Lawlor et al., 2008). To further assess the robustness of MR estimates, we examined evidence of heterogeneity across individual SNPs using the Cochran Q-statistic, which indicates the presence of invalid instruments (e.g., due to horizontal pleiotropy), if Q is much larger than its degrees of freedom (No. of instrumental variables minus 1) (Bowden et al., 2018). MR-PRESSO (Mendelian Randomization Pleiotropy RESidual Sum and Outlier) was used to detect and correct for potential outliers (where Q-statistic p < 0.05) (Verbanck et al., 2018).

Instrument-risk factor effects

Request a detailed protocol

Where there was evidence for an effect of a metabolic trait on oral or oropharyngeal cancer risk in the primary MR analysis, we conducted further evaluation of the metabolic instruments onto established HNC risk factors using two-sample MR. The largest available GWAS were used for smoking initiation (a binary phenotype indicating whether an individual had ever smoked in their life versus never smokers) (n = 1,232,091) and alcoholic drinks per week (defined as the average number of drinks per week aggregated across all types of alcohol, n = 941,280) from the GWAS and Sequencing Consortium of Alcohol and Nicotine use (GSCAN) study (Liu et al., 2019). The comprehensive smoking index, a quantitative lifetime measure of smoking behaviour derived from 462,690 individuals from UK Biobank was also employed. A 1 standard deviation (SD) increase in the index is equivalent to an individual smoking 20 cigarettes a day for 15 years and stopping 17 years ago, or an individual smoking 60 cigarettes a day for 13 years and stopping 22 years ago.

Summary statistics were also obtained from a GWAS of general risk tolerance (n = 939,908), derived from a meta-analysis of UK Biobank (n = 431,126) binary question ‘Would you describe yourself as someone who takes risks?’ and the 23andMe (n = 508,782) question ‘Overall, do you feel comfortable or uncomfortable taking risks?’. The GWAS of risk tolerance was based on one’s tendency or willingness to take risks, making them more likely to engage in risk-taking behaviours more generally (Karlsson Linnér et al., 2019). A strong genetic correlation between sexual behaviours and risk tolerance has been shown previously (Gormley et al., 2022). Finally, given the known association between HNC and lower socioeconomic position, we used MR to examine educational attainment (defined by years of schooling) (Lee et al., 2018). Outcome beta estimates reflect the standard deviation of the phenotype.

Data availability

Summary-level analysis was conducted using publicly available GWAS data as cited. Full summary statistics for the GAME-ON outcome data GWAS can be accessed via dbGAP (OncoArray: Oral and Pharynx Cancer; study accession number: phs001202.v1.p1, August 2017) at: https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001202.v1.p1 (Lesseur et al., 2016). This data is also available via the IEU OpenGWAS project (https://gwas.mrcieu.ac.uk/). All exposure data used in this study is publicly available from the relevant studies as described below. Data for BMI, WC and WHR GWAS was downloaded from the Genetic Investigation of ANthropometric Traits (GIANT) consortium https://portals.broadinstitute.org/collaboration/giant/index.php/GIANT_consortium_data_files (Pulit et al., 2019; Shungin et al., 2015) and UK Biobank (http://www.ukbiobank.ac.uk). T2D data was downloaded from the DIAMANTE (DIAbetes Meta-ANalysis of Trans-Ethnic association studies) consortium from: https://kp4cd.org/node/169 (Vujkovic et al., 2020). Data for FG, FI, and HbA1c were obtained from GWAS published by the MAGIC (Meta-Analyses of Glucose and Insulin-Related Traits) Consortium, available for download from: https://magicinvestigators.org/downloads/ (Lagou et al., 2021),. Finally, data for SBP and DBP were extracted from a GWAS meta-analysis of participants in UK Biobank and UK Biobank (http://www.ukbiobank.ac.uk) and the International Consortium of Blood Pressure Genome Wide Association Studies (ICBP), available via dbGAP (International Consortium for Blood Pressure (ICBP), study accession number: phs000585.v2.p1, October 2016) at https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000585.v2.p1 (Evangelou et al., 2018). Instrument-risk factor analysis outcome summary-level data were derived from the GWAS and Sequencing Consortium of Alcohol and Nicotine use (GSCAN) and UK Biobank and UK Biobank (http://www.ukbiobank.ac.uk) for alcoholic drinks per week https://conservancy.umn.edu/handle/11299/201564 (Liu et al., 2019) and the comprehensive smoking index (Wootton et al., 2020). Data for risk tolerance and educational attainment were taken from Social Science Genetic Association Consortium (SSGAC) data available from http://www.thessgac.org/data (Karlsson Linnér et al., 2019; Lee et al., 2018). MR analyses were conducted using the 'TwoSampleMR' package in R (version 3.5.3). A copy of the code and all data files used in this study are available at GitHub (https://github.com/MGormley12/metabolic_trait_hnc_mr.git copy archived at Gormley, 2023).

The following previously published data sets were used
    1. Pulit SL
    (2018) Zenodo
    Summary-level data from meta-analysis of fat distribution phenotypes in UK Biobank and GIANT.
    https://doi.org/10.5281/zenodo.1251813
    1. Evangelou E
    (2016) NCBI BioProject
    ID phs000585.v2.p1. International Consortium for Blood Pressure (ICBP).
    https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000585.v2.p1
    1. Liu M
    (2019) DRUM
    Data Related to Association studies of up to 1.2 million individuals yield new insights into the genetic etiology of tobacco and alcohol use.
    https://doi.org/10.13020/3b1n-ff32

References

    1. Evangelou E
    2. Warren HR
    3. Mosen-Ansorena D
    4. Mifsud B
    5. Pazoki R
    6. Gao H
    7. Ntritsos G
    8. Dimou N
    9. Cabrera CP
    10. Karaman I
    11. Ng FL
    12. Evangelou M
    13. Witkowska K
    14. Tzanis E
    15. Hellwege JN
    16. Giri A
    17. Velez Edwards DR
    18. Sun YV
    19. Cho K
    20. Gaziano JM
    21. Wilson PWF
    22. Tsao PS
    23. Kovesdy CP
    24. Esko T
    25. Mägi R
    26. Milani L
    27. Almgren P
    28. Boutin T
    29. Debette S
    30. Ding J
    31. Giulianini F
    32. Holliday EG
    33. Jackson AU
    34. Li-Gao R
    35. Lin WY
    36. Luan J
    37. Mangino M
    38. Oldmeadow C
    39. Prins BP
    40. Qian Y
    41. Sargurupremraj M
    42. Shah N
    43. Surendran P
    44. Thériault S
    45. Verweij N
    46. Willems SM
    47. Zhao JH
    48. Amouyel P
    49. Connell J
    50. de Mutsert R
    51. Doney ASF
    52. Farrall M
    53. Menni C
    54. Morris AD
    55. Noordam R
    56. Paré G
    57. Poulter NR
    58. Shields DC
    59. Stanton A
    60. Thom S
    61. Abecasis G
    62. Amin N
    63. Arking DE
    64. Ayers KL
    65. Barbieri CM
    66. Batini C
    67. Bis JC
    68. Blake T
    69. Bochud M
    70. Boehnke M
    71. Boerwinkle E
    72. Boomsma DI
    73. Bottinger EP
    74. Braund PS
    75. Brumat M
    76. Campbell A
    77. Campbell H
    78. Chakravarti A
    79. Chambers JC
    80. Chauhan G
    81. Ciullo M
    82. Cocca M
    83. Collins F
    84. Cordell HJ
    85. Davies G
    86. de Borst MH
    87. de Geus EJ
    88. Deary IJ
    89. Deelen J
    90. Del Greco M. F
    91. Demirkale CY
    92. Dörr M
    93. Ehret GB
    94. Elosua R
    95. Enroth S
    96. Erzurumluoglu AM
    97. Ferreira T
    98. Frånberg M
    99. Franco OH
    100. Gandin I
    101. Gasparini P
    102. Giedraitis V
    103. Gieger C
    104. Girotto G
    105. Goel A
    106. Gow AJ
    107. Gudnason V
    108. Guo X
    109. Gyllensten U
    110. Hamsten A
    111. Harris TB
    112. Harris SE
    113. Hartman CA
    114. Havulinna AS
    115. Hicks AA
    116. Hofer E
    117. Hofman A
    118. Hottenga JJ
    119. Huffman JE
    120. Hwang SJ
    121. Ingelsson E
    122. James A
    123. Jansen R
    124. Jarvelin MR
    125. Joehanes R
    126. Johansson Å
    127. Johnson AD
    128. Joshi PK
    129. Jousilahti P
    130. Jukema JW
    131. Jula A
    132. Kähönen M
    133. Kathiresan S
    134. Keavney BD
    135. Khaw KT
    136. Knekt P
    137. Knight J
    138. Kolcic I
    139. Kooner JS
    140. Koskinen S
    141. Kristiansson K
    142. Kutalik Z
    143. Laan M
    144. Larson M
    145. Launer LJ
    146. Lehne B
    147. Lehtimäki T
    148. Liewald DCM
    149. Lin L
    150. Lind L
    151. Lindgren CM
    152. Liu Y
    153. Loos RJF
    154. Lopez LM
    155. Lu Y
    156. Lyytikäinen LP
    157. Mahajan A
    158. Mamasoula C
    159. Marrugat J
    160. Marten J
    161. Milaneschi Y
    162. Morgan A
    163. Morris AP
    164. Morrison AC
    165. Munson PJ
    166. Nalls MA
    167. Nandakumar P
    168. Nelson CP
    169. Niiranen T
    170. Nolte IM
    171. Nutile T
    172. Oldehinkel AJ
    173. Oostra BA
    174. O’Reilly PF
    175. Org E
    176. Padmanabhan S
    177. Palmas W
    178. Palotie A
    179. Pattie A
    180. Penninx B
    181. Perola M
    182. Peters A
    183. Polasek O
    184. Pramstaller PP
    185. Nguyen QT
    186. Raitakari OT
    187. Ren M
    188. Rettig R
    189. Rice K
    190. Ridker PM
    191. Ried JS
    192. Riese H
    193. Ripatti S
    194. Robino A
    195. Rose LM
    196. Rotter JI
    197. Rudan I
    198. Ruggiero D
    199. Saba Y
    200. Sala CF
    201. Salomaa V
    202. Samani NJ
    203. Sarin AP
    204. Schmidt R
    205. Schmidt H
    206. Shrine N
    207. Siscovick D
    208. Smith AV
    209. Snieder H
    210. Sõber S
    211. Sorice R
    212. Starr JM
    213. Stott DJ
    214. Strachan DP
    215. Strawbridge RJ
    216. Sundström J
    217. Swertz MA
    218. Taylor KD
    219. Teumer A
    220. Tobin MD
    221. Tomaszewski M
    222. Toniolo D
    223. Traglia M
    224. Trompet S
    225. Tuomilehto J
    226. Tzourio C
    227. Uitterlinden AG
    228. Vaez A
    229. van der Most PJ
    230. van Duijn CM
    231. Vergnaud AC
    232. Verwoert GC
    233. Vitart V
    234. Völker U
    235. Vollenweider P
    236. Vuckovic D
    237. Watkins H
    238. Wild SH
    239. Willemsen G
    240. Wilson JF
    241. Wright AF
    242. Yao J
    243. Zemunik T
    244. Zhang W
    245. Attia JR
    246. Butterworth AS
    247. Chasman DI
    248. Conen D
    249. Cucca F
    250. Danesh J
    251. Hayward C
    252. Howson JMM
    253. Laakso M
    254. Lakatta EG
    255. Langenberg C
    256. Melander O
    257. Mook-Kanamori DO
    258. Palmer CNA
    259. Risch L
    260. Scott RA
    261. Scott RJ
    262. Sever P
    263. Spector TD
    264. van der Harst P
    265. Wareham NJ
    266. Zeggini E
    267. Levy D
    268. Munroe PB
    269. Newton-Cheh C
    270. Brown MJ
    271. Metspalu A
    272. Hung AM
    273. O’Donnell CJ
    274. Edwards TL
    275. Psaty BM
    276. Tzoulaki I
    277. Barnes MR
    278. Wain LV
    279. Elliott P
    280. Caulfield MJ
    281. the Million Veteran Program
    (2018) Genetic analysis of over 1 million people identifies 535 new loci associated with blood pressure traits
    Nature Genetics 50:1412–1425.
    https://doi.org/10.1038/s41588-018-0205-x
    1. Lagou V
    2. Mägi R
    3. Hottenga JJ
    4. Grallert H
    5. Perry JRB
    6. Bouatia-Naji N
    7. Marullo L
    8. Rybin D
    9. Jansen R
    10. Min JL
    11. Dimas AS
    12. Ulrich A
    13. Zudina L
    14. Gådin JR
    15. Jiang L
    16. Faggian A
    17. Bonnefond A
    18. Fadista J
    19. Stathopoulou MG
    20. Isaacs A
    21. Willems SM
    22. Navarro P
    23. Tanaka T
    24. Jackson AU
    25. Montasser ME
    26. O’Connell JR
    27. Bielak LF
    28. Webster RJ
    29. Saxena R
    30. Stafford JM
    31. Pourcain BS
    32. Timpson NJ
    33. Salo P
    34. Shin SY
    35. Amin N
    36. Smith AV
    37. Li G
    38. Verweij N
    39. Goel A
    40. Ford I
    41. Johnson PCD
    42. Johnson T
    43. Kapur K
    44. Thorleifsson G
    45. Strawbridge RJ
    46. Rasmussen-Torvik LJ
    47. Esko T
    48. Mihailov E
    49. Fall T
    50. Fraser RM
    51. Mahajan A
    52. Kanoni S
    53. Giedraitis V
    54. Kleber ME
    55. Silbernagel G
    56. Meyer J
    57. Müller-Nurasyid M
    58. Ganna A
    59. Sarin AP
    60. Yengo L
    61. Shungin D
    62. Luan J
    63. Horikoshi M
    64. An P
    65. Sanna S
    66. Boettcher Y
    67. Rayner NW
    68. Nolte IM
    69. Zemunik T
    70. Iperen E
    71. Kovacs P
    72. Hastie ND
    73. Wild SH
    74. McLachlan S
    75. Campbell S
    76. Polasek O
    77. Carlson O
    78. Egan J
    79. Kiess W
    80. Willemsen G
    81. Kuusisto J
    82. Laakso M
    83. Dimitriou M
    84. Hicks AA
    85. Rauramaa R
    86. Bandinelli S
    87. Thorand B
    88. Liu Y
    89. Miljkovic I
    90. Lind L
    91. Doney A
    92. Perola M
    93. Hingorani A
    94. Kivimaki M
    95. Kumari M
    96. Bennett AJ
    97. Groves CJ
    98. Herder C
    99. Koistinen HA
    100. Kinnunen L
    101. Faire U de
    102. Bakker SJL
    103. Uusitupa M
    104. Palmer CNA
    105. Jukema JW
    106. Sattar N
    107. Pouta A
    108. Snieder H
    109. Boerwinkle E
    110. Pankow JS
    111. Magnusson PK
    112. Krus U
    113. Scapoli C
    114. de Geus E
    115. Blüher M
    116. Wolffenbuttel BHR
    117. Province MA
    118. Abecasis GR
    119. Meigs JB
    120. Hovingh GK
    121. Lindström J
    122. Wilson JF
    123. Wright AF
    124. Dedoussis GV
    125. Bornstein SR
    126. Schwarz PEH
    127. Tönjes A
    128. Winkelmann BR
    129. Boehm BO
    130. März W
    131. Metspalu A
    132. Price JF
    133. Deloukas P
    134. Körner A
    135. Lakka TA
    136. Keinanen-Kiukaanniemi SM
    137. Saaristo TE
    138. Bergman RN
    139. Tuomilehto J
    140. Wareham NJ
    141. Langenberg C
    142. Männistö S
    143. Franks PW
    144. Hayward C
    145. Vitart V
    146. Kaprio J
    147. Visvikis-Siest S
    148. Balkau B
    149. Altshuler D
    150. Rudan I
    151. Stumvoll M
    152. Campbell H
    153. van Duijn CM
    154. Gieger C
    155. Illig T
    156. Ferrucci L
    157. Pedersen NL
    158. Pramstaller PP
    159. Boehnke M
    160. Frayling TM
    161. Shuldiner AR
    162. Peyser PA
    163. Kardia SLR
    164. Palmer LJ
    165. Penninx BW
    166. Meneton P
    167. Harris TB
    168. Navis G
    169. Harst P
    170. Smith GD
    171. Forouhi NG
    172. Loos RJF
    173. Salomaa V
    174. Soranzo N
    175. Boomsma DI
    176. Groop L
    177. Tuomi T
    178. Hofman A
    179. Munroe PB
    180. Gudnason V
    181. Siscovick DS
    182. Watkins H
    183. Lecoeur C
    184. Vollenweider P
    185. Franco-Cereceda A
    186. Eriksson P
    187. Jarvelin MR
    188. Stefansson K
    189. Hamsten A
    190. Nicholson G
    191. Karpe F
    192. Dermitzakis ET
    193. Lindgren CM
    194. McCarthy MI
    195. Froguel P
    196. Kaakinen MA
    197. Lyssenko V
    198. Watanabe RM
    199. Ingelsson E
    200. Florez JC
    201. Dupuis J
    202. Barroso I
    203. Morris AP
    204. Prokopenko I
    205. Meta-Analyses of Glucose and Insulin-related traits Consortium
    (2021) Publisher correction: Sex-dimorphic genetic effects and novel loci for fasting glucose and insulin variability
    Nature Communications 12:995.
    https://doi.org/10.1038/s41467-021-21276-3
    1. Mills MC
    2. Tropf FC
    3. Brazel DM
    4. van Zuydam N
    5. Vaez A
    6. eQTLGen Consortium
    7. Agbessi M
    8. Ahsan H
    9. Alves I
    10. Andiappan AK
    11. Arindrarto W
    12. Awadalla P
    13. Battle A
    14. Beutner F
    15. Jan Bonder M
    16. Boomsma DI
    17. Christiansen MW
    18. Claringbould A
    19. Deelen P
    20. Esko T
    21. Favé M-J
    22. Franke L
    23. Frayling T
    24. Gharib SA
    25. Gibson G
    26. Heijmans BT
    27. Hemani G
    28. Jansen R
    29. Kähönen M
    30. Kalnapenkis A
    31. Kasela S
    32. Kettunen J
    33. Kim Y
    34. Kirsten H
    35. Kovacs P
    36. Krohn K
    37. Kronberg J
    38. Kukushkina V
    39. Kutalik Z
    40. Lee B
    41. Lehtimäki T
    42. Loeffler M
    43. Marigorta UM
    44. Mei H
    45. Milani L
    46. Montgomery GW
    47. Müller-Nurasyid M
    48. Nauck M
    49. Nivard MG
    50. Penninx BWJH
    51. Perola M
    52. Pervjakova N
    53. Pierce BL
    54. Powell J
    55. Prokisch H
    56. Psaty BM
    57. Raitakari OT
    58. Ripatti S
    59. Rotzschke O
    60. Rüeger S
    61. Saha A
    62. Scholz M
    63. Schramm K
    64. Seppälä I
    65. Slagboom EP
    66. Stehouwer CDA
    67. Stumvoll M
    68. Sullivan P
    69. ‘t Hoen PAC
    70. Teumer A
    71. Thiery J
    72. Tong L
    73. Tönjes A
    74. van Dongen J
    75. van Iterson M
    76. van Meurs J
    77. Veldink JH
    78. Verlouw J
    79. Visscher PM
    80. Völker U
    81. Võsa U
    82. Westra HJ
    83. Wijmenga C
    84. Yaghootkar H
    85. Yang J
    86. Zeng B
    87. Zhang F
    88. BIOS Consortium
    89. Management Team
    90. Heijmans BT
    91. ‘t Hoen PAC
    92. van Meurs J
    93. Isaacs A
    94. Jansen R
    95. Franke L
    96. Cohort collection
    97. Boomsma DI
    98. Pool R
    99. van Dongen J
    100. Jan Hottenga J
    101. van Greevenbroek MMJ
    102. Stehouwer CDA
    103. van der Kallen CJH
    104. Schalkwijk CG
    105. Wijmenga C
    106. Franke L
    107. Zhernakova S
    108. Tigchelaar EF
    109. Slagboom EP
    110. Beekman M
    111. Deelen J
    112. van Heemst D
    113. Veldink JH
    114. van den Berg LH
    115. van Duijn CM
    116. Hofman BA
    117. Isaacs A
    118. Uitterlinden AG
    119. Data Generation
    120. van Meurs J
    121. Jhamai PM
    122. Verbiest M
    123. Suchiman HED
    124. Verkerk M
    125. van der Breggen R
    126. van Rooij J
    127. Lakenberg N
    128. Data management and computational infrastructure
    129. Mei H
    130. van Iterson M
    131. van Galen M
    132. Bot J
    133. Zhernakova DV
    134. Jansen R
    135. van ’t Hof P
    136. Deelen P
    137. Nooren I
    138. ‘t Hoen PAC
    139. Heijmans BT
    140. Moed M
    141. Data Analysis Group
    142. Franke L
    143. Vermaat M
    144. Zhernakova DV
    145. Luijk R
    146. Jan Bonder M
    147. van Iterson M
    148. Deelen P
    149. van Dijk F
    150. van Galen M
    151. Arindrarto W
    152. Kielbasa SM
    153. Swertz MA
    154. van Zwet EW
    155. Jansen R
    156. ‘t Hoen PAC
    157. Heijmans BT
    158. Human Reproductive Behaviour Consortium
    159. Akimova ET
    160. Bergmann S
    161. Boardman JD
    162. Boomsma DI
    163. Brumat M
    164. Buring JE
    165. Cesarini D
    166. Chasman DI
    167. Chavarro JE
    168. Cocca M
    169. Concas MP
    170. Davey-Smith G
    171. Davies G
    172. Deary IJ
    173. Esko T
    174. Franco O
    175. Gaskins AJ
    176. de Geus EJC
    177. Gieger C
    178. Girotto G
    179. Grabe HJ
    180. Gunderson EP
    181. Harris KM
    182. Hartwig FP
    183. He C
    184. van Heemst D
    185. Hill WD
    186. Homuth G
    187. Horta BL
    188. Jan Hottenga J
    189. Huang H
    190. Hyppӧnen E
    191. Ikram MA
    192. Jansen R
    193. Johannesson M
    194. Kamali Z
    195. Kavousi M
    196. Kraft P
    197. Kühnel B
    198. Langenberg C
    199. Lifelines Cohort Study
    200. Lind PA
    201. Luan J
    202. Mägi R
    203. Magnusson PKE
    204. Mahajan A
    205. Martin NG
    206. Mbarek H
    207. McCarthy MI
    208. McMahon G
    209. McQueen MB
    210. Medland SE
    211. Meitinger T
    212. Metspalu A
    213. Mihailov E
    214. Milani L
    215. Missmer SA
    216. Møllegaard S
    217. Mook-Kanamori DO
    218. Morgan A
    219. van der Most PJ
    220. de Mutsert R
    221. Nauck M
    222. Nolte IM
    223. Noordam R
    224. Penninx BWJH
    225. Peters A
    226. Power C
    227. Redmond P
    228. Rich-Edwards JW
    229. Ridker PM
    230. Rietveld CA
    231. Ring SM
    232. Rose LM
    233. Rueedi R
    234. Stefánsson K
    235. Stöckl D
    236. Strauch K
    237. Swertz MA
    238. Teumer A
    239. Thorleifsson G
    240. Thorsteinsdottir U
    241. Thurik AR
    242. Timpson NJ
    243. Turman C
    244. Uitterlinden AG
    245. Waldenberger M
    246. Wareham NJ
    247. Willemsen G
    248. Zhao JH
    249. Pers TH
    250. Snieder H
    251. Perry JRB
    252. Ong KK
    253. den Hoed M
    254. Barban N
    255. Day FR
    (2021) Identification of 371 genetic variants for age at first sex and birth linked to externalising behaviour
    Nature Human Behaviour 5:1717–1730.
    https://doi.org/10.1038/s41562-021-01135-3
    1. Shungin D
    2. Winkler TW
    3. Croteau-Chonka DC
    4. Ferreira T
    5. Locke AE
    6. Mägi R
    7. Strawbridge RJ
    8. Pers TH
    9. Fischer K
    10. Justice AE
    11. Workalemahu T
    12. Wu JMW
    13. Buchkovich ML
    14. Heard-Costa NL
    15. Roman TS
    16. Drong AW
    17. Song C
    18. Gustafsson S
    19. Day FR
    20. Esko T
    21. Fall T
    22. Kutalik Z
    23. Luan J
    24. Randall JC
    25. Scherag A
    26. Vedantam S
    27. Wood AR
    28. Chen J
    29. Fehrmann R
    30. Karjalainen J
    31. Kahali B
    32. Liu C-T
    33. Schmidt EM
    34. Absher D
    35. Amin N
    36. Anderson D
    37. Beekman M
    38. Bragg-Gresham JL
    39. Buyske S
    40. Demirkan A
    41. Ehret GB
    42. Feitosa MF
    43. Goel A
    44. Jackson AU
    45. Johnson T
    46. Kleber ME
    47. Kristiansson K
    48. Mangino M
    49. Leach IM
    50. Medina-Gomez C
    51. Palmer CD
    52. Pasko D
    53. Pechlivanis S
    54. Peters MJ
    55. Prokopenko I
    56. Stančáková A
    57. Sung YJ
    58. Tanaka T
    59. Teumer A
    60. Van Vliet-Ostaptchouk JV
    61. Yengo L
    62. Zhang W
    63. Albrecht E
    64. Ärnlöv J
    65. Arscott GM
    66. Bandinelli S
    67. Barrett A
    68. Bellis C
    69. Bennett AJ
    70. Berne C
    71. Blüher M
    72. Böhringer S
    73. Bonnet F
    74. Böttcher Y
    75. Bruinenberg M
    76. Carba DB
    77. Caspersen IH
    78. Clarke R
    79. Daw EW
    80. Deelen J
    81. Deelman E
    82. Delgado G
    83. Doney AS
    84. Eklund N
    85. Erdos MR
    86. Estrada K
    87. Eury E
    88. Friedrich N
    89. Garcia ME
    90. Giedraitis V
    91. Gigante B
    92. Go AS
    93. Golay A
    94. Grallert H
    95. Grammer TB
    96. Gräßler J
    97. Grewal J
    98. Groves CJ
    99. Haller T
    100. Hallmans G
    101. Hartman CA
    102. Hassinen M
    103. Hayward C
    104. Heikkilä K
    105. Herzig K-H
    106. Helmer Q
    107. Hillege HL
    108. Holmen O
    109. Hunt SC
    110. Isaacs A
    111. Ittermann T
    112. James AL
    113. Johansson I
    114. Juliusdottir T
    115. Kalafati I-P
    116. Kinnunen L
    117. Koenig W
    118. Kooner IK
    119. Kratzer W
    120. Lamina C
    121. Leander K
    122. Lee NR
    123. Lichtner P
    124. Lind L
    125. Lindström J
    126. Lobbens S
    127. Lorentzon M
    128. Mach F
    129. Magnusson PK
    130. Mahajan A
    131. McArdle WL
    132. Menni C
    133. Merger S
    134. Mihailov E
    135. Milani L
    136. Mills R
    137. Moayyeri A
    138. Monda KL
    139. Mooijaart SP
    140. Mühleisen TW
    141. Mulas A
    142. Müller G
    143. Müller-Nurasyid M
    144. Nagaraja R
    145. Nalls MA
    146. Narisu N
    147. Glorioso N
    148. Nolte IM
    149. Olden M
    150. Rayner NW
    151. Renstrom F
    152. Ried JS
    153. Robertson NR
    154. Rose LM
    155. Sanna S
    156. Scharnagl H
    157. Scholtens S
    158. Sennblad B
    159. Seufferlein T
    160. Sitlani CM
    161. Smith AV
    162. Stirrups K
    163. Stringham HM
    164. Sundström J
    165. Swertz MA
    166. Swift AJ
    167. Syvänen A-C
    168. Tayo BO
    169. Thorand B
    170. Thorleifsson G
    171. Tomaschitz A
    172. Troffa C
    173. van Oort FV
    174. Verweij N
    175. Vonk JM
    176. Waite LL
    177. Wennauer R
    178. Wilsgaard T
    179. Wojczynski MK
    180. Wong A
    181. Zhang Q
    182. Zhao JH
    183. Brennan EP
    184. Choi M
    185. Eriksson P
    186. Folkersen L
    187. Franco-Cereceda A
    188. Gharavi AG
    189. Hedman ÅK
    190. Hivert M-F
    191. Huang J
    192. Kanoni S
    193. Karpe F
    194. Keildson S
    195. Kiryluk K
    196. Liang L
    197. Lifton RP
    198. Ma B
    199. McKnight AJ
    200. McPherson R
    201. Metspalu A
    202. Min JL
    203. Moffatt MF
    204. Montgomery GW
    205. Murabito JM
    206. Nicholson G
    207. Nyholt DR
    208. Olsson C
    209. Perry JR
    210. Reinmaa E
    211. Salem RM
    212. Sandholm N
    213. Schadt EE
    214. Scott RA
    215. Stolk L
    216. Vallejo EE
    217. Westra H-J
    218. Zondervan KT
    219. Amouyel P
    220. Arveiler D
    221. Bakker SJ
    222. Beilby J
    223. Bergman RN
    224. Blangero J
    225. Brown MJ
    226. Burnier M
    227. Campbell H
    228. Chakravarti A
    229. Chines PS
    230. Claudi-Boehm S
    231. Collins FS
    232. Crawford DC
    233. Danesh J
    234. de Faire U
    235. de Geus EJ
    236. Dörr M
    237. Erbel R
    238. Eriksson JG
    239. Farrall M
    240. Ferrannini E
    241. Ferrières J
    242. Forouhi NG
    243. Forrester T
    244. Franco OH
    245. Gansevoort RT
    246. Gieger C
    247. Gudnason V
    248. Haiman CA
    249. Harris TB
    250. Hattersley AT
    251. Heliövaara M
    252. Hicks AA
    253. Hingorani AD
    254. Hoffmann W
    255. Hofman A
    256. Homuth G
    257. Humphries SE
    258. Hyppönen E
    259. Illig T
    260. Jarvelin M-R
    261. Johansen B
    262. Jousilahti P
    263. Jula AM
    264. Kaprio J
    265. Kee F
    266. Keinanen-Kiukaanniemi SM
    267. Kooner JS
    268. Kooperberg C
    269. Kovacs P
    270. Kraja AT
    271. Kumari M
    272. Kuulasmaa K
    273. Kuusisto J
    274. Lakka TA
    275. Langenberg C
    276. Le Marchand L
    277. Lehtimäki T
    278. Lyssenko V
    279. Männistö S
    280. Marette A
    281. Matise TC
    282. McKenzie CA
    283. McKnight B
    284. Musk AW
    285. Möhlenkamp S
    286. Morris AD
    287. Nelis M
    288. Ohlsson C
    289. Oldehinkel AJ
    290. Ong KK
    291. Palmer LJ
    292. Penninx BW
    293. Peters A
    294. Pramstaller PP
    295. Raitakari OT
    296. Rankinen T
    297. Rao DC
    298. Rice TK
    299. Ridker PM
    300. Ritchie MD
    301. Rudan I
    302. Salomaa V
    303. Samani NJ
    304. Saramies J
    305. Sarzynski MA
    306. Schwarz PE
    307. Shuldiner AR
    308. Staessen JA
    309. Steinthorsdottir V
    310. Stolk RP
    311. Strauch K
    312. Tönjes A
    313. Tremblay A
    314. Tremoli E
    315. Vohl M-C
    316. Völker U
    317. Vollenweider P
    318. Wilson JF
    319. Witteman JC
    320. Adair LS
    321. Bochud M
    322. Boehm BO
    323. Bornstein SR
    324. Bouchard C
    325. Cauchi S
    326. Caulfield MJ
    327. Chambers JC
    328. Chasman DI
    329. Cooper RS
    330. Dedoussis G
    331. Ferrucci L
    332. Froguel P
    333. Grabe H-J
    334. Hamsten A
    335. Hui J
    336. Hveem K
    337. Jöckel K-H
    338. Kivimaki M
    339. Kuh D
    340. Laakso M
    341. Liu Y
    342. März W
    343. Munroe PB
    344. Njølstad I
    345. Oostra BA
    346. Palmer CN
    347. Pedersen NL
    348. Perola M
    349. Pérusse L
    350. Peters U
    351. Power C
    352. Quertermous T
    353. Rauramaa R
    354. Rivadeneira F
    355. Saaristo TE
    356. Saleheen D
    357. Sinisalo J
    358. Slagboom PE
    359. Snieder H
    360. Spector TD
    361. Stefansson K
    362. Stumvoll M
    363. Tuomilehto J
    364. Uitterlinden AG
    365. Uusitupa M
    366. van der Harst P
    367. Veronesi G
    368. Walker M
    369. Wareham NJ
    370. Watkins H
    371. Wichmann H-E
    372. Abecasis GR
    373. Assimes TL
    374. Berndt SI
    375. Boehnke M
    376. Borecki IB
    377. Deloukas P
    378. Franke L
    379. Frayling TM
    380. Groop LC
    381. Hunter DJ
    382. Kaplan RC
    383. O’Connell JR
    384. Qi L
    385. Schlessinger D
    386. Strachan DP
    387. Thorsteinsdottir U
    388. van Duijn CM
    389. Willer CJ
    390. Visscher PM
    391. Yang J
    392. Hirschhorn JN
    393. Zillikens MC
    394. McCarthy MI
    395. Speliotes EK
    396. North KE
    397. Fox CS
    398. Barroso I
    399. Franks PW
    400. Ingelsson E
    401. Heid IM
    402. Loos RJ
    403. Cupples LA
    404. Morris AP
    405. Lindgren CM
    406. Mohlke KL
    407. ADIPOGen Consortium
    408. CARDIOGRAMplusC4D Consortium
    409. CKDGen Consortium
    410. GEFOS Consortium
    411. GENIE Consortium
    412. GLGC
    413. ICBP
    414. International Endogene Consortium
    415. LifeLines Cohort Study
    416. MAGIC Investigators
    417. MuTHER Consortium
    418. PAGE Consortium
    419. ReproGen Consortium
    (2015) New genetic loci link adipose and insulin biology to body fat distribution
    Nature 518:187–196.
    https://doi.org/10.1038/nature14132
    1. Wheeler E
    2. Leong A
    3. Liu C-T
    4. Hivert M-F
    5. Strawbridge RJ
    6. Podmore C
    7. Li M
    8. Yao J
    9. Sim X
    10. Hong J
    11. Chu AY
    12. Zhang W
    13. Wang X
    14. Chen P
    15. Maruthur NM
    16. Porneala BC
    17. Sharp SJ
    18. Jia Y
    19. Kabagambe EK
    20. Chang L-C
    21. Chen W-M
    22. Elks CE
    23. Evans DS
    24. Fan Q
    25. Giulianini F
    26. Go MJ
    27. Hottenga J-J
    28. Hu Y
    29. Jackson AU
    30. Kanoni S
    31. Kim YJ
    32. Kleber ME
    33. Ladenvall C
    34. Lecoeur C
    35. Lim S-H
    36. Lu Y
    37. Mahajan A
    38. Marzi C
    39. Nalls MA
    40. Navarro P
    41. Nolte IM
    42. Rose LM
    43. Rybin DV
    44. Sanna S
    45. Shi Y
    46. Stram DO
    47. Takeuchi F
    48. Tan SP
    49. van der Most PJ
    50. Van Vliet-Ostaptchouk JV
    51. Wong A
    52. Yengo L
    53. Zhao W
    54. Goel A
    55. Martinez Larrad MT
    56. Radke D
    57. Salo P
    58. Tanaka T
    59. van Iperen EPA
    60. Abecasis G
    61. Afaq S
    62. Alizadeh BZ
    63. Bertoni AG
    64. Bonnefond A
    65. Böttcher Y
    66. Bottinger EP
    67. Campbell H
    68. Carlson OD
    69. Chen C-H
    70. Cho YS
    71. Garvey WT
    72. Gieger C
    73. Goodarzi MO
    74. Grallert H
    75. Hamsten A
    76. Hartman CA
    77. Herder C
    78. Hsiung CA
    79. Huang J
    80. Igase M
    81. Isono M
    82. Katsuya T
    83. Khor C-C
    84. Kiess W
    85. Kohara K
    86. Kovacs P
    87. Lee J
    88. Lee W-J
    89. Lehne B
    90. Li H
    91. Liu J
    92. Lobbens S
    93. Luan J
    94. Lyssenko V
    95. Meitinger T
    96. Miki T
    97. Miljkovic I
    98. Moon S
    99. Mulas A
    100. Müller G
    101. Müller-Nurasyid M
    102. Nagaraja R
    103. Nauck M
    104. Pankow JS
    105. Polasek O
    106. Prokopenko I
    107. Ramos PS
    108. Rasmussen-Torvik L
    109. Rathmann W
    110. Rich SS
    111. Robertson NR
    112. Roden M
    113. Roussel R
    114. Rudan I
    115. Scott RA
    116. Scott WR
    117. Sennblad B
    118. Siscovick DS
    119. Strauch K
    120. Sun L
    121. Swertz M
    122. Tajuddin SM
    123. Taylor KD
    124. Teo Y-Y
    125. Tham YC
    126. Tönjes A
    127. Wareham NJ
    128. Willemsen G
    129. Wilsgaard T
    130. Hingorani AD
    131. Egan J
    132. Ferrucci L
    133. Hovingh GK
    134. Jula A
    135. Kivimaki M
    136. Kumari M
    137. Njølstad I
    138. Palmer CNA
    139. Serrano Ríos M
    140. Stumvoll M
    141. Watkins H
    142. Aung T
    143. Blüher M
    144. Boehnke M
    145. Boomsma DI
    146. Bornstein SR
    147. Chambers JC
    148. Chasman DI
    149. Chen Y-DI
    150. Chen Y-T
    151. Cheng C-Y
    152. Cucca F
    153. de Geus EJC
    154. Deloukas P
    155. Evans MK
    156. Fornage M
    157. Friedlander Y
    158. Froguel P
    159. Groop L
    160. Gross MD
    161. Harris TB
    162. Hayward C
    163. Heng C-K
    164. Ingelsson E
    165. Kato N
    166. Kim B-J
    167. Koh W-P
    168. Kooner JS
    169. Körner A
    170. Kuh D
    171. Kuusisto J
    172. Laakso M
    173. Lin X
    174. Liu Y
    175. Loos RJF
    176. Magnusson PKE
    177. März W
    178. McCarthy MI
    179. Oldehinkel AJ
    180. Ong KK
    181. Pedersen NL
    182. Pereira MA
    183. Peters A
    184. Ridker PM
    185. Sabanayagam C
    186. Sale M
    187. Saleheen D
    188. Saltevo J
    189. Schwarz PE
    190. Sheu WHH
    191. Snieder H
    192. Spector TD
    193. Tabara Y
    194. Tuomilehto J
    195. van Dam RM
    196. Wilson JG
    197. Wilson JF
    198. Wolffenbuttel BHR
    199. Wong TY
    200. Wu J-Y
    201. Yuan J-M
    202. Zonderman AB
    203. Soranzo N
    204. Guo X
    205. Roberts DJ
    206. Florez JC
    207. Sladek R
    208. Dupuis J
    209. Morris AP
    210. Tai E-S
    211. Selvin E
    212. Rotter JI
    213. Langenberg C
    214. Barroso I
    215. Meigs JB
    216. EPIC-CVD Consortium
    217. EPIC-InterAct Consortium
    218. Lifelines Cohort Study
    (2017) Impact of common genetic determinants of hemoglobin a1c on type 2 diabetes risk and diagnosis in ancestrally diverse populations: A transethnic genome-wide meta-analysis
    PLOS Medicine 14:e1002383.
    https://doi.org/10.1371/journal.pmed.1002383

Article and author information

Author details

  1. Mark Gormley

    1. MRC Integrative Epidemiology Unit, Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, United Kingdom
    2. Bristol Dental Hospital and School, University of Bristol, Bristol, United Kingdom
    Contribution
    Conceptualization, Data curation, Formal analysis, Funding acquisition, Investigation, Visualization, Methodology, Writing – original draft, Project administration, Writing – review and editing
    For correspondence
    mark.gormley@bristol.ac.uk
    Competing interests
    No competing interests declared
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-5733-6304

  2. Tom Dudding

    Bristol Dental Hospital and School, University of Bristol, Bristol, United Kingdom
    Contribution
    Conceptualization, Methodology, Writing – review and editing
    Competing interests
    No competing interests declared

  3. Steven J Thomas

    Bristol Dental Hospital and School, University of Bristol, Bristol, United Kingdom
    Contribution
    Supervision, Writing – review and editing
    Competing interests
    No competing interests declared

  4. Jessica Tyrrell

    University of Exeter Medical School, RILD Building, RD&E Hospital, Exeter, United Kingdom
    Contribution
    Supervision, Methodology, Writing – review and editing
    Competing interests
    No competing interests declared

  5. Andrew R Ness

    University Hospitals Bristol and Weston NHS Foundation Trust National Institute for Health Research Bristol Biomedical Research Centre, University of Bristol, Bristol, United Kingdom
    Contribution
    Conceptualization, Supervision, Writing – review and editing
    Competing interests
    No competing interests declared

  6. Miranda Pring

    Bristol Dental Hospital and School, University of Bristol, Bristol, United Kingdom
    Contribution
    Supervision, Writing – review and editing
    Competing interests
    No competing interests declared

  7. Danny Legge

    Translational Health Sciences, Bristol Medical School, University of Bristol, Bristol, United Kingdom
    Contribution
    Supervision, Writing – review and editing
    Competing interests
    No competing interests declared
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-3897-5861

  8. George Davey Smith

    MRC Integrative Epidemiology Unit, Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, United Kingdom
    Contribution
    Conceptualization, Supervision, Methodology, Writing – original draft, Writing – review and editing
    Competing interests
    No competing interests declared
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-1407-8314

  9. Rebecca C Richmond

    MRC Integrative Epidemiology Unit, Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, United Kingdom
    Contribution
    Conceptualization, Supervision, Methodology, Writing – review and editing
    Competing interests
    No competing interests declared

  10. Emma E Vincent

    1. MRC Integrative Epidemiology Unit, Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, United Kingdom
    2. Translational Health Sciences, Bristol Medical School, University of Bristol, Bristol, United Kingdom
    Contribution
    Conceptualization, Supervision, Methodology, Writing – original draft, Writing – review and editing
    Contributed equally with
    Caroline Bull
    Competing interests
    No competing interests declared
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-8917-7384

  11. Caroline Bull

    1. MRC Integrative Epidemiology Unit, Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, United Kingdom
    2. Translational Health Sciences, Bristol Medical School, University of Bristol, Bristol, United Kingdom
    Contribution
    Conceptualization, Formal analysis, Supervision, Validation, Investigation, Visualization, Methodology, Writing – original draft, Writing – review and editing
    Contributed equally with
    Emma E Vincent
    Competing interests
    No competing interests declared
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-2176-5120

Funding

Wellcome Trust (220530/Z/20/Z)

  • Mark Gormley

Diabetes UK (SBF004\1079)

  • Jessica Tyrrell

National Institute for Health and Care Research (RP-PG-0707-10034)

  • Andrew R Ness

Cancer Research UK (C18281/A20919)

  • Andrew R Ness

National Institute of Dental and Craniofacial Research (R01 DE025712 and 1X01HG007780-0)

  • Andrew R Ness

Diabetes UK (17/0005587)

  • Emma E Vincent

World Cancer Research Fund (IIG_2019_2009)

  • Emma E Vincent

Medical Research Council (MC_UU_00011/1)

  • George Davey Smith

Medical Research Council (MC_UU_00011/5)

  • George Davey Smith

Medical Research Council (MC_UU_00011/6)

  • George Davey Smith

Medical Research Council (MC_UU_00011/7)

  • George Davey Smith

The funders had no role in study design, data collection, and interpretation, or the decision to submit the work for publication. For the purpose of Open Access, the authors have applied a CC BY public copyright license to any Author Accepted Manuscript version arising from this submission.

Acknowledgements

M.G. was a National Institute for Health Research (NIHR) academic clinical fellow and is currently supported by a Wellcome Trust GW4-Clinical Academic Training PhD Fellowship. This research was funded in part, by the Wellcome Trust [Grant number 220530/Z/20/Z]. For the purpose of open access, the author has applied a CC BY public copyright licence to any Author Accepted Manuscript version arising from this submission. R.C.R. is a de Pass VC research fellow at the University of Bristol. J.T. is supported by an Academy of Medical Sciences (AMS) Springboard award, which is supported by the AMS, the Wellcome Trust, Global Challenges Research Fund (GCRF), the Government Department of Business, Energy and Industrial strategy, the British Heart Foundation and Diabetes UK (SBF004\1079). A.R.N. was supported by the National Institute for Health Research (NIHR) Bristol Biomedical Research Centre which is funded by the National Institute for Health Research (NIHR) and is a partnership between University Hospitals Bristol NHS Foundation Trust and the University of Bristol. Department of Health and Social Care disclaimer: The views expressed are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health and Social Care. This publication presents data from the Head and Neck 5000 which contributes to international VOYAGER and HEADSpAcE head and neck cancer consortia. The Head and Neck 5000 study was a component of independent research funded by the National Institute for Health Research (NIHR) under its Programme Grants for Applied Research scheme (RP-PG-0707-10034). The views expressed in this publication are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health. Core funding was also provided through awards from Above and Beyond, University Hospitals Bristol and Weston Research Capability Funding and the NIHR Senior Investigator award to A.R.N. Human papillomavirus (HPV) serology was supported by a Cancer Research UK Programme Grant, the Integrative Cancer Epidemiology Programme (C18281/A20919). The VOYAGER study was supported in part by the US National Institute of Dental and Craniofacial Research (NIDCR; R01 DE025712). The genotyping of the HNC cases and controls was performed at the Center for Inherited Disease Research (CIDR) and funded by the US National Institute of Dental and Craniofacial Research (NIDCR; 1X01HG007780-0). E.E.V., C.B., and D.L. are supported by Diabetes UK (17/0005587). E.E.V. and C.B. are supported by the World Cancer Research Fund (WCRF UK), as part of the World Cancer Research Fund International grant programme (IIG_2019_2009). M.G., T.D., G.D.S., E.E.V., R.C.R., and C.B. are part of the Medical Research Council Integrative Epidemiology Unit at the University of Bristol supported by the Medical Research Council (MC_UU_00011/1, MC_UU_00011/5, MC_UU_00011/6, MC_UU_00011/7).

Ethics

Publicly available summary-level data only used in this study. Application entitled 'Investigating aetiology, associations and causality in diseases of the head and neck' (Project ID: 40644) covers use of all UK Biobank data in this study and dbGaP application made for accessing OncoArray: Oral and Pharynx Cancer; study accession number: phs001202.v1.p1 data entitled 'Investigating risk factors in head and neck cancer using Mendelian randomization' (Project ID 24266). All studies included as part of the GAME-ON network obtained approval and consent from their respective institutions.

Copyright

© 2023, Gormley et al.

This article is distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 1,111
    views
  • 163
    downloads
  • 18
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Mark Gormley
  2. Tom Dudding
  3. Steven J Thomas
  4. Jessica Tyrrell
  5. Andrew R Ness
  6. Miranda Pring
  7. Danny Legge
  8. George Davey Smith
  9. Rebecca C Richmond
  10. Emma E Vincent
  11. Caroline Bull
(2023)
Evaluating the effect of metabolic traits on oral and oropharyngeal cancer risk using Mendelian randomization
eLife 12:e82674.
https://doi.org/10.7554/eLife.82674

Share this article

https://doi.org/10.7554/eLife.82674

Categories and tags

Research organism

Further reading

    1. Cell Biology
    2. Genetics and Genomics

    Full-length direct RNA sequencing uncovers stress granule-dependent RNA decay upon cellular stress

    Showkat Ahmad Dar, Sulochan Malla ... Manolis Maragkakis
    Research Article

    Cells react to stress by triggering response pathways, leading to extensive alterations in the transcriptome to restore cellular homeostasis. The role of RNA metabolism in shaping the cellular response to stress is vital, yet the global changes in RNA stability under these conditions remain unclear. In this work, we employ direct RNA sequencing with nanopores, enhanced by 5ʹ end adapter ligation, to comprehensively interrogate the human transcriptome at single-molecule and -nucleotide resolution. By developing a statistical framework to identify robust RNA length variations in nanopore data, we find that cellular stress induces prevalent 5ʹ end RNA decay that is coupled to translation and ribosome occupancy. Unlike typical RNA decay models in normal conditions, we show that stress-induced RNA decay is dependent on XRN1 but does not depend on deadenylation or decapping. We observed that RNAs undergoing decay are predominantly enriched in the stress granule transcriptome while inhibition of stress granule formation via genetic ablation of G3BP1 and G3BP2 rescues RNA length. Our findings reveal RNA decay as a key component of RNA metabolism upon cellular stress that is dependent on stress granule formation.

    1. Genetics and Genomics
    2. Neuroscience

    Statistical examination of shared loci in neuropsychiatric diseases using genome-wide association study summary statistics

    Thomas P Spargo, Lachlan Gilchrist ... Alfredo Iacoangeli
    Research Article

    Continued methodological advances have enabled numerous statistical approaches for the analysis of summary statistics from genome-wide association studies. Genetic correlation analysis within specific regions enables a new strategy for identifying pleiotropy. Genomic regions with significant ‘local’ genetic correlations can be investigated further using state-of-the-art methodologies for statistical fine-mapping and variant colocalisation. We explored the utility of a genome-wide local genetic correlation analysis approach for identifying genetic overlaps between the candidate neuropsychiatric disorders, Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS), frontotemporal dementia, Parkinson’s disease, and schizophrenia. The correlation analysis identified several associations between traits, the majority of which were loci in the human leukocyte antigen region. Colocalisation analysis suggested that disease-implicated variants in these loci often differ between traits and, in one locus, indicated a shared causal variant between ALS and AD. Our study identified candidate loci that might play a role in multiple neuropsychiatric diseases and suggested the role of distinct mechanisms across diseases despite shared loci. The fine-mapping and colocalisation analysis protocol designed for this study has been implemented in a flexible analysis pipeline that produces HTML reports and is available at: https://github.com/ThomasPSpargo/COLOC-reporter.

    1. Chromosomes and Gene Expression
    2. Genetics and Genomics

    A genome-wide nucleosome-resolution map of promoter-centered interactions in human cells corroborates the enhancer-promoter looping model

    Arkadiy K Golov, Alexey A Gavrilov ... Sergey V Razin
    Research Article

    The enhancer-promoter looping model, in which enhancers activate their target genes via physical contact, has long dominated the field of gene regulation. However, the ubiquity of this model has been questioned due to evidence of alternative mechanisms and the lack of its systematic validation, primarily owing to the absence of suitable experimental techniques. In this study, we present a new MNase-based proximity ligation method called MChIP-C, allowing for the measurement of protein-mediated chromatin interactions at single-nucleosome resolution on a genome-wide scale. By applying MChIP-C to study H3K4me3 promoter-centered interactions in K562 cells, we found that it had greatly improved resolution and sensitivity compared to restriction endonuclease-based C-methods. This allowed us to identify EP300 histone acetyltransferase and the SWI/SNF remodeling complex as potential candidates for establishing and/or maintaining enhancer-promoter interactions. Finally, leveraging data from published CRISPRi screens, we found that most functionally verified enhancers do physically interact with their cognate promoters, supporting the enhancer-promoter looping model.